Dosing is limited to the inhalation route.  This restricts its usage, as treating asthmatics could induce [[bronchospasm]]s.<ref name="Hayden">{{cite journal | author = Hayden FG |title = Perspectives on antiviral use during pandemic influenza | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 356| issue = 1416 | pages = 1877–84 |date=December 2001 | pmid = 11779387 | pmc = 1088564 | doi = 10.1098/rstb.2001.1007}}</ref> In 2006 the [[Food and Drug Administration|Food and Drug Administration (FDA)]] found that breathing problems (bronchospasm), including deaths, were reported in some patients after the initial approval of Relenza. Most of these patients had asthma or chronic obstructive pulmonary disease. Relenza therefore was not recommended for treatment or prophylaxis of seasonal influenza in individuals with asthma or chronic obstructive pulmonary disease.<ref name="FDA 2006">{{cite web|title=FDA Approves a Second Drug for the Prevention of Influenza A and B in Adults and Children|url=http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108622.htm|publisher=FDA press release}}</ref>  In 2009 the zanamivir package insert contains precautionary information regarding risk of bronchospasm in patients with respiratory disease.<ref name="fda">{{cite web | url=http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052240.htm | title=Safe and Appropriate Use of Influenza Drugs | work=Public Health Advisories (Drugs) | publisher= [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) | date=April 30, 2009 | accessdate = 2009-11-11 | archiveurl = https://web.archive.org/web/20091104104758/http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052240.htm | archivedate = 2009-11-04}}</ref>

 
GlaxoSmithKline (GSK) and FDA notified healthcare professionals of a report of the death of a patient with influenza having received zanamivir inhalation powder, which was solubilized and administered by mechanical ventilation.<ref>http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm</ref>

 


 
In adults there was no increased risk of reported adverse events in trials. There was little evidence of the possible harms associated with the treatment of children with zanamivir.<ref name="cochrane 2014" /> 

 
Zanamivir has not been known to cause toxic effects and has low systemic exposure to the human body.<ref>{{cite journal|last=Freund|first=B|author2=Gravenstein, S |author3=Elliott, M |author4= Miller, I |title=Zanamivir: a review of clinical safety.|journal=Drug safety : an international journal of medical toxicology and drug experience|date=Oct 1999|volume=21|issue=4|pages=267–81|pmid=10514019 |doi=10.2165/00002018-199921040-00003}}</ref>

 

